4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
AssigneeAstraZeneca AB
InventorsXiaomei Feng, Huiping Guan, Ying Kan, Stephanos Ioannidis, Bo Peng, Mei Su, Bin Wang, Tao Wang, Hai-Jun Zhang
Life of this patent
Estimating the term…
Abstract
This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
Claims20
A compound of formula (I):
- wherein:
- R1 is selected from hydrogen, hydroxy, amino, mercapto, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, C1-6alkylsulphonylamino, 3-5-membered carbocyclyl or 3-5-membered heterocyclyl;
- wherein R1 may be optionally substituted on carbon by one or more R6;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R7;
- R2 and R3 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, (C1-6alkyl)2N—S(O)2—NH—, (C1-6alkyl)NH—S(O)2—NH—, NH2—S(O)2—NH—, (C1-6alkyl)2N—S(O)2—N(C1-6alkyl)-, (C1-6alkyl)NH—S(O)2—N(C1-6alkyl)-, NH2—S(O)2—N(C1-6alkyl)-, N—(C1-6alkyl)-N—(C1-6alkylsulphonyl)amino, C1-6alkylsulphonylamino, carbocyclyl-R19— or heterocyclyl-R21—;
- wherein R2 and R3 independently of each other may be optionally substituted on carbon by one or more R8;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;
- R4 is selected from cyano, carboxy, carbamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkanoyl, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkoxycarbonyl, carbocyclyl or heterocyclyl;
- wherein R4 may be optionally substituted on carbon by one or more R10;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R11;
- R5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl;
- wherein R5 may be optionally substituted on carbon by one or more R12;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;
- n=0, 1, 2 or 3;
- wherein the values of R5 may be the same or different;
- R6, R8, R10 and R12 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl;
- wherein R6, R8, R10 and R12 independently of each other may be optionally substituted on carbon by one or more R14;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R15;
- R7, R9, R11, R13 and R15 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
- wherein R7, R9, R11, R13 and R15 independently of each other may be optionally substituted on carbon by on or more R16;
- R14 and R16 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl;
- wherein R14 and R16 independently of each other may be optionally substituted on carbon by one or more R17;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R18;
- R17 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;
- and
- R19 and R21 are independently selected from a direct bond, —O—, —N(R22)—, —C(O)—, —N(R23)C(O)—, —C(O)N(R24)—, —S(O)S—, —SO2N(R25)— or —N(R26)SO2—;
- wherein R22, R23,
- R24, R25 and R26 are independently selected from hydrogen or C1-6alkyl and s is 0-2;
- and
- R18 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
- or a pharmaceutically acceptable salt thereof.
A compound of formula (I),
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is selected from the group consisting of methyl, methoxy, trifluoroethoxy, isopropoxy, cyclopropyl, and N,N-dimethylamino;
- R2 is selected from the group consisting of hydrogen, chloro, fluoro, bromo, nitro, and trifluoromethyl;
- R3 is selected from the group consisting of hydrogen, chloro, cyano, trifluoromethyl, (CH3)2N—S(O)2—N(CH3)—, N-methyl-N-mesylamino, and morpholino;
- R4 is methyl;
- R5 is fluoro;
- and
- n is 1.
12-19. (canceled)
The method of claim 17, wherein said cancer is selected from the group consisting of oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal cancer, lymphoma and leukaemia.
27-33. (canceled)
Dependencies are inferred from the claim text.